Iron deficiency and ferroptosis in gynecology. Possible corrections: A review of the literature

Abstract

The review presents the main aspects of iron deficiency anemia (IDA) in women of reproductive age and highlights current diagnostic methods, therapy, and prevention of IDA. Moreover, the paper presents contemporary views on the molecular mechanisms of iron metabolism and iron homeostasis disruption involved in endometriosis. The role of laboratory tests in the diagnosis of latent and symptomatic iron deficiency of extreme importance was also described. In addition to IDA, anemia also occurs in patients with chronic gynecological diseases with a different pathogenesis. Its mechanisms were reported in the study discussed in the review. The results of the study on ferroptosis in patients with endometriosis were demonstrated, which showed significantly levels of iron, ferritin, lipid hydroperoxide, and low-density lipoprotein were higher in the peritoneal fluid of women with endometriosis than in healthy women. The paper provided current information on the treatment of IDA in gynecology, possible symptomatic hypophosphatemia after intravenous therapy with iron-containing drugs, and methods to treat this complication. Current data on ferroptosis, its effect on the body, and ways of inducing, and inhibiting this process were presented.

Keywords

iron deficiency anemia / iron metabolism / diagnosis of iron deficiency anemia / treatment of iron deficiency anemia / iron(III) hydroxide oligoisomaltosate / iron(III) carboxymaltosate / hypermagnesemia / ferroptosis / endometriosis

References

[1] Elstrott B, Khan L, Olson S, et al. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020;104(3):153–161. doi: 10.1111/ejh.13345

[2] Elstrott B., Khan L., Olson S., et al. The role of iron repletion in adult iron deficiency anemia and other diseases // Eur J Haematol. 2020. Vol. 104, N. 3. P. 153–161. doi: 10.1111/ejh.13345

[3] Kalinkina OB, Tezikov YuV, Lipatov IS. Management tactics of patients with hyperplastic syndrome and anemia. Medical and Pharmaceutical Journal “Pulse”. 2022;24(5):122–127. (In Russ).doi: 10.26787/nydha-2686-6838-2022-24-5-122-127

[4] Калинкина О.Б., Тезиков Ю.В., Липатов И.С. Тактика ведения пациенток с гиперпластическим синдромом и анемией // Медико-фармакологический журнал «Пульс». 2022. Т. 24, № 5. С. 122–127. doi: 10.26787/nydha-2686-6838-2022-24-5-122-127

[5] Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management. Hematology Am Soc Hematol Educ Program. 2017;2017(1):152–159.doi: 10.1182/asheducation-2017.1.152

[6] Breymann C., Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management // Hematology Am Soc Hematol Educ Program. 2017. Vol. 2017, N. 1. P. 152–159.doi: 10.1182/asheducation-2017.1.152

[7] Dobrokhotova YuE, Khlynova SA. Correction of Iron Deficiency Anemia in Gynecological Patients. Lechebnoe delo. 2017;(3):31–36. (In Russ).

[8] Доброхотова Ю.Э., Хлынова С.А. Коррекция железодефицитной анемии у гинекологических больных // Лечебное дело. 2017. № 3. С. 31–36.

[9] Dobroсhotova YuE, Karanasheva AKh. Antianemic Treatment of Patients with Submucosal Uterine Myoma after Uterine Artery Embolization. Lechebnoe delo. 2021;(4):52–56. (In Russ). doi: 10.24412/2071-5315-2021-12393

[10] Доброхотова Ю.Э., Каранашева А.Х. Антианемическая терапия у больных с субмукозной миомой матки после эмболизации маточных артерий // Лечебное дело. 2021. № 4. С. 52–56.doi: 10.24412/2071-5315-2021-12393

[11] Bolotova EV, Dudnikova AV, Krutova VA. Frequency and features of iron-deficient conditions in women of reproductive age. Clinical Medicine (Russian Journal). 2020;98(4):287–293. (In Russ).doi: 10.30629/0023-2149-2020-98-4-287-293

[12] Болотова Е.В., Дудникова А.В., Крутова В.А. Частота и особенности железодефицитных состояний у женщин репродуктивного возраста // Клиническая медицина. 2020. Т. 98, № 4. С. 287–293.doi: 10.34651/0023-2149-2020-98-4-287-29

[13] Dixon SJ, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.doi: 10.1016/j.cell.2012.03.042

[14] Dixon S.J., Stockwell B.R. Ferroptosis: an iron-dependent form of nonapoptotic cell death // Cell. 2012. Vol. 149, N. 5. P. 1060–1072. doi: 10.1016/j.cell.2012.03.042

[15] Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–379. doi: 10.1038/cdd.2015.158

[16] Xie Y., Hou W., Song X., et al. Ferroptosis: process and function // Cell Death Differ. 2016. Vol. 23, N. 3. P. 369–379.doi: 10.1038/cdd.2015.158

[17] DeLoughery TG. Iron Deficiency Anemia. Med Clin North Am. 2017;101(2):319–332. doi: 10.1016/j.mcna.2016.09.004

[18] DeLoughery T.G. Iron Deficiency Anemia // Med Clin North Am. 2017. Vol. 101, N. 2. P. 319–332. doi: 10.1016/j.mcna.2016.09.004

[19] Briguglio M, Hrelia S, Malaguti M, et al. The Central Role of Iron in Human Nutrition: From Folk to Contemporary Medicine. Nutrients. 2020;12(6):1761. doi: 10.3390/nu12061761

[20] Briguglio M., Hrelia S., Malaguti M., et al. The Central Role of Iron in Human Nutrition: From Folk to Contemporary Medicine // Nutrients. 2020. Vol. 12, N. 6. P. 1761. doi: 10.3390/nu12061761

[21] Surzhikova GS, Klochkova-Abelyants SA. Proteins-regulators of iron metabolism in the differential diagnosis of iron-deficiency anemia. Medicine in Kuzbass. 2022;(3):36–40. (In Russ).doi: 10.24412/2687-0053-2022-3-36-40

[22] Суржикова Г.С., Клочкова-Абельянц С.А. Белки-регуляторы метаболизма железа в дифференциальной диагностике железодефицитных анемий // Медицина в Кузбассе. 2022. № 3. С. 36–40. doi: 10.24412/2687-0053-2022-3-36-40

[23] Lv J, Hou B, Song J, Xu Y, Xie S. The Relationship Between Ferroptosis and Diseases. J Multidiscip Healthc. 2022;15:2261–2275. doi: 10.2147/JMDH.S382643

[24] Lv J., Hou B., Song J., Xu Y., Xie S. The Relationship Between Ferroptosis and Diseases // J Multidiscip Healthc. 2022. Vol. 15. P. 2261–2275. doi: 10.2147/JMDH.S382643

[25] Vartanian AA. Iron metabolism, ferroptosis and cancer. Russian Journal of Biotherapy. 2017;16(3):14–20. (In Russ).doi: 10.17650/1726-9784-2017-16-3-14-20

[26] Вартанян А.А. Метаболизм железа, ферроптоз, рак // Российский биотерапевтический журнал. 2017. Том 16, № 3. С. 14–20. doi: 10.17650/1726-9784-2017-16-3-14-20

[27] Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285–296. doi: 10.1016/s1535-6108(03)00050-3

[28] Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells // Cancer Cell. 2003. Vol. 3, N. 3. P. 285–296.doi: 10.1016/s1535-6108(03)00050-3

[29] Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–245. doi: 10.1016/j.chembiol.2008.02.010

[30] Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells // Chem Biol. 2008. Vol. 15, N. 3. P. 234–245. doi: 10.1016/j.chembiol.2008.02.010

[31] Bedford MR, Ford SJ, Horniblow RD, Iqbal TH, Tselepis Ch. Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol. 2013;53(9):885–891. doi: 10.1002/jcph.113

[32] Bedford M.R., Ford S.J., Horniblow R.D., Iqbal T.H., Tselepis Ch. Iron chelation in the treatment of cancer: a new role for deferasirox? // J Clin Pharmacol. 2013. Vol. 53, N. 9. P. 885–891.doi: 10.1002/jcph.113

[33] Ludwig H, Evstatiev R, Kornek G, et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015;127(23–24):907–919. doi: 10.1007/s00508-015-0842-3

[34] Ludwig H., Evstatiev R., Kornek G., et al. Iron metabolism and iron supplementation in cancer patients // Wien Klin Wochenschr. 2015. Vol. 127, N. 23–24. P. 907–919.doi: 10.1007/s00508-015-0842-3

[35] Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna). 2016;123(4):389–399.doi: 10.1007/s00702-016-1508-7

[36] Li K., Reichmann H. Role of iron in neurodegenerative diseases // J Neural Transm (Vienna). 2016. Vol. 123, N. 4. P. 389–399. doi: 10.1007/s00702-016-1508-7

[37] Yu H, Guo P, Xie X, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21(4):648–657. doi: 10.1111/jcmm.13008

[38] Yu H., Guo P., Xie X., et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases // J Cell Mol Med. 2017. Vol. 21, N. 4. P. 648–657. doi: 10.1111/jcmm.13008

[39] Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: The Role of Iron Overload and Ferroptosis. Reprod Sci. 2020;27(7):1383–1390. doi: 10.1007/s43032-020-00164-z

[40] Ng S.W., Norwitz S.G., Taylor H.S., Norwitz E.R. Endometriosis: The Role of Iron Overload and Ferroptosis // Reprod Sci. 2020. Vol. 27, N. 7. P. 1383–1390. doi: 10.1007/s43032-020-00164-z

[41] Li Y, Zeng X, Lu D, et al. Erastin induces apoptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod. 2021;36(4):951–964. doi: 10.1093/humrep/deaa363

[42] Li Y., Zeng X., Lu D., et al. Erastin induces apoptosis via ferroportin-mediated iron accumulation in endometriosis // Hum Reprod. 2021. Vol. 36, N. 4. P. 951–964. doi: 10.1093/humrep/deaa363

[43] National Hematology Society, National Society of Pediatric Hematologists and Oncologists. Zhelezodefitsitnaya anemiya. Klinicheskie rekomendatsii (approved by the Ministry of Health of the Russian Federation in 2021).Available from: JDA_2021_klin_rek.pdf (In Russ).

[44] Национальное гематологическое общество, Национальное общество детских гематологов и онкологов. Железодефицитная анемия. Клинические рекомендации (утверждены Минздравом РФ в 2021 г.). Режим доступа: JDA_2021_klin_rek.pdf Дата обращения: 05.03.2023.

[45] Daru J, Colman K, Stanworth SJ, et al. Serum ferritin as an indicator of iron status: what do we need to know? Am J Clin Nutr. 2017;106 Suppl.6:1634S–1639S. doi: 10.3945/ajcn.117.155960

[46] Daru J., Colman K., Stanworth S.J., et al. Serum ferritin as an indicator of iron status: what do we need to know? // Am J Clin Nutr. 2017. Vol. 106, Suppl. 6. P. 1634S–1639S.doi: 10.3945/ajcn.117.155960

[47] Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017;31(4):225–233.doi: 10.1016/j.blre.2017.02.004

[48] Camaschella C. New insights into iron deficiency and iron deficiency anemia // Blood Rev. 2017. Vol. 31, N. 4. P. 225–233.doi: 10.1016/j.blre.2017.02.004

[49] Lukina EA, Ledina AV, Rogovskaya SI. Iron-deficiency anemia: a view of hematologist and gynecologist. Optimizing diagnostic and treatment approach. Russian Journal of Woman and Child Health. 2020;3(4):248–253. (In Russ).doi: 10.32364/2618-8430-2020-3-4-248-253

[50] Лукина Е.А., Ледина А.В., Роговская С.И. Железодефицитная анемия: взгляд гематолога и гинеколога. Оптимизируем диагностику и лечебную тактику // Русский медицинский журнал. Мать и дитя. 2020. Т. 3, № 4. С. 248–253.doi: 10.32364/2618-8430-2020-3-4-248-253

[51] Bouri S, Martin J. Investigation of iron deficiency anaemia. Clin Med (Lond). 2018;18(3):242–244.doi: 10.7861/clinmedicine.18-3-242

[52] Bouri S., Martin J. Investigation of iron deficiency anaemia // Clin Med (Lond). 2018. Vol. 18, N. 3. P. 242–244.doi: 10.7861/clinmedicine.18-3-242

[53] Ozolinya LA, Boldina EB. Treatment of anemia in gynecological patients. Obstetrics and Gynecology. 2010;(6):135–139. (In Russ).

[54] Озолиня Л.А., Болдина Е.Б. Лечение анемии у гинекологических больных // Акушерство и гинекология. 2010. № 6. C. 135–139.

[55] Ozolinya LA, Shirenina AA, Kulinicheva EA. Modern possibilities of iron deficiency anemia treatment in one visit. V.F. Snegirev Archives of Obstetrics and Gynecology. 2019;6(4):185–192. (In Russ). doi: 10.18821/2313-8726-2019-6-4-185-192

[56] Озолиня Л.А., Ширенина А.А., Кулиничева Е.А. Современные возможности лечения железодефицитной анемии за один визит // Архив акушерства и гинекологии им. В.Ф. Снегирёва. 2019. Т. 6, № 4. С. 185–192. doi: 10.18821/2313-8726-2019-6-4-185-192

[57] Ozolinya LA, Savchenko TN, Golovko ED. Correction of iron deficiency in patients with abnormal uterine bleeding. V.F. Snegirev Archives of Obstetrics and Gynecology. 2022;9(3):173–180. (In Russ). doi: 10.17816/2313-8726-2022-9-3-173-180

[58] Озолиня Л.А., Савченко Т.Н., Головко Е.Д. Коррекция железодефицитных состояний при аномальных маточных кровотечениях // Архив акушерства и гинекологии им. В.Ф. Снегирёва. 2022. Т. 9, № 3. С. 173–180. doi: 10.17816/2313-8726-2022-9-3-173-180

[59] Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside ― a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256–2273.doi: 10.1111/bcp.14643

[60] Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside ― a systematic review and meta-analysis // Br J Clin Pharmacol. 2021. Vol. 87, N. 5. P. 2256–2273.doi: 10.1111/bcp.14643

[61] Yagudina RI, Kulikov AYu, Serpik VG, Gromova OA, Torshin IYu. Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):73–86. (In Russ).doi: 10.17749/2070-4909/farmakoekonomika.2022.124

[62] Ягудина Р.И., Куликов А.Ю., Серпик В.Г., Громова О.А., Торшин И.Ю. Фармакоэкономический анализ препарата Монофер для использования у пациентов с железодефицитной анемией в рамках оказания медицинской помощи по программе госгарантий в условиях системы здравоохранения Российской Федерации // ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022. Т. 15, № 1. С. 73–86.doi: 10.17749/2070-4909/farmakoekonomika.2022.124

[63] Borisova LM, Golubeva IS, Kiseleva MP. Molecular determinants of ferroptosis. Siberian Medical Journal. 2019;158(3):11–16. (In Russ). doi: 10.34673/ismu.2020.49.16.002

[64] Борисова Л.М., Голубева И.С., Киселева М.П. Молекулярные характеристики ферроптоза // Сибирский медицинский журнал (Иркутск). 2019. Т. 158, № 3. С. 11–16.doi: 10.34673/ismu.2020.49.16.002

[65] Maldonado EN, Sheldon KL, DeHart DN, et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. J Biol Chem. 2013;288(17):11920–11929.doi: 10.1074/jbc.M112.433847

[66] Maldonado E.N., Sheldon K.L., DeHart D.N., et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin // J Biol Chem. 2013. Vol. 288, N. 17. P. 11920–11929.doi: 10.1074/jbc.M112.433847

[67] Huo H, Zhou Z, Qin J, et al. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells. PLoS One. 2016;11(5):e0154605.doi: 10.1371/journal.pone.0154605

[68] Huo H., Zhou Z., Qin J., et al. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells // PLoS One. 2016. Vol. 11, N. 5. P. e0154605. doi: 10.1371/journal.pone.0154605

[69] Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22(11):1045–1054.doi: 10.1016/j.phymed.2015.08.002

[70] Ooko E., Saeed M.E., Kadioglu O., et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells // Phytomedicine. 2015. Vol. 22, N. 11. P. 1045–1054.doi: 10.1016/j.phymed.2015.08.002

RIGHTS & PERMISSIONS

Eco-Vector